BioSeeker launches new report "New Targets and Drug Discovery Platforms in Antifungal R&D"
According to the Antifungal
Work Group at NIH there is a “critical need for the development of
antifungal agents“. The urgency stems from the therapeutic limitations
of the present antifungal compounds development of fungal drug resistant,
drug-related toxicity, hazardous drug-drug interactions and non-optimal
pharmacokinetics. This makes them inadequate in prophylactic treatments
for immuno-compromised patient, such as HIV infected and patients with
ongoing cancer or transplantation treatment. The wish for a safe
prophylactic antifungal therapy may not be far away from being realized,
and a success would certainly provide substantial revenues.
During the 1990’s, the
U.S. systemic antifungal market has grown by 25% per year. The estimated
health care cost is $35 0000 US dollars per Medicare patient (The fifth
NIAID Workshop in Medical Mycology 2000). With roughly 30 000 patients
infected with Candida nosocomial bloodstream infection per year, annual
costs just for candidemia exceed $1bn US.
In this report, we provide
an overview and assessment of emerging drug targets and screening assays.
We place special emphasis on glycosylphosphatidylinositol (GPI) anchoring,
ABC phospholipid translocators, elongation factor-2 and calcineurin.
Extensive scientific research is conducted in these areas and important
breakthrough are expected earlier than for other novel targets. Many novel
targets for antifungal therapy are in research or early stage of
development, preclinical or phase I studies, and will take at least five
to ten years to reach the market. A very recent addition is Demegen’s
new lead antifungal compound based on the antifungal D-amino acid Histatin
based peptides, expected to reach phase I trials soon.
This 52-page report focus
on recent achievements made in antifungal target discovery and screening
assays used to identify novel lead antifungal compounds. BioSeeker Group
has identified 50 companies involved in this development. Their recent
activities are described
Topics considered in
this report:
Research: identified
targets and new asssay for screening
Patents: selected near-term
key patents
Clinical trials:
indications, status and activities
Partnerships: key
collaborations for success
Companies included in
the report:
Discovery Laboratories,
Abbott Laboratories, Advanced Bio-Technologies, Anadys, Applied Genomics,
ARIAD Pharmaceuticals, Inc, Arrow Therapeutics , Astrazeneca, Aventis ,
Bayer-AG, Bioqual Inc., Bristol-Myers Squibb, Celera , Demegen, Discovery
Technologies, Dyadic , Eisai Co Ltd, Eli Lilly, Elitra, Essential
Therapeutics, Fujisawa Pharmaceutical Co, Genelabs, GlaxoSmithKline, GPC
Biotech Inc, Isis Innovation Ltd, Janssen Pharmaceutica, LG Chemical,
Merck, MerLion Pharma, Microbia Inc., Millennium Pharm Inc, Mycologics,
Neutec Pharma Plc, NewBiotics, Inc., Novartis, Novo Nordisk AS, Pfizer,
Pharmacia Corp., Pliva Pharmaceutical, Roche, Rosetta Inpharmatics Inc.,
Wyeth (American Home Prod), Sankyo Co., Ltd, Searle & Co, Toyama
Chemical Co., Ltd., Tularik Inc., VDDI Pharmaceuticals, Xencor, Inc, Xoma
Technology, Zeneca
To
order go to: http://www.bioportfolio.com/cgi-bin/acatalog/search.html
and search by title.
Or
click
here!
